BLA 021148 · Novo Nordisk INC
Norditropin Flexpro
Somatropin · Injection · Recombinant Human Growth Hormone
OrphanLast checked: Nov 20, 2026Latest source record: Jul 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Jun 20, 2000
Approved uses
7
Original approval plus efficacy supplements
Registered trials
540
176 Phase 3, 31 recruiting
FAERS reports
9,514
6,529 serious, 504 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 7, 2025.
NORDITROPIN is a recombinant human growth hormone indicated for: • Pediatric : Treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature associated with Noonan syndrome, short stature associated with Turner syndrome, short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4 years, Idiopathic Short Stature (ISS), and growth failure due to Prader-Willi Syndrome ( 1.1 ) • Adult : Replacement of endogenous GH in adults with growth hormone deficiency ( 1.2 ) 1.1 Pediatric Patients NORDITROPIN is indicated for the treatment of pediatric patients with: • growth failure due to inadequate secretion of endogenous growth hormone (GH), • short stature associated with Noonan syndrome, • short stature associated with Turner syndrome, • short stature born small for gestational age (SGA) with no catch-up growth by age 2 years to 4 years of age, • Idiopathic Short Stature (ISS), height standard deviation score (SDS) <-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, • growth failure due to Prader-Willi syndrome (PWS). 1.2 Adult Patients NORDITROPIN is indicated for the replacement of endogenous GH in adults with growth hormone deficiency (GHD)
Mechanism: Somatropin binds to dimeric GH receptors located within the cell membranes of target tissue cells. This interaction results in intracellular signal transduction and subsequent induction of transcription and translation of GH-dependent proteins including IGF-1, IGF BP-3 and acid-labile subunit. Somatropin has direct tissue and metabolic effects or mediated indirectly by IGF-1, including stimulation of chondrocyte differentiation, and proliferation, stimulation hepatic glucose output, protein synthesis and lipolysis. Somatropin stimulates skeletal growth in pediatric patients with GHD as a...
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 23, 2018 Supplement 37 · Efficacy LetterLabel
- Feb 23, 2018 Supplement 38 · Efficacy LetterLabel
- Oct 31, 2008 Supplement 23 · Efficacy LetterLabel
- Sep 20, 2007 Supplement 17 · Efficacy LabelLetter
- May 31, 2007 Supplement 16 · Efficacy LetterLabel
- Nov 1, 2004 Supplement 7 · Efficacy Letter
- Jun 20, 2000 Original approval · Type 3 - New Dosage Form OtherReviewLetter
11 products under this application
- NORDITROPIN FLEXPRO · SOMATROPIN 5MG/1.5ML · INJECTABLE, INJECTION · Prescription
- NORDITROPIN NORDIFLEX · SOMATROPIN 15MG/1.5ML · INJECTABLE, INJECTION · Discontinued
- NORDITROPIN NORDIFLEX · SOMATROPIN 5MG/1.5ML · INJECTABLE, INJECTION · Discontinued
- NORDITROPIN FLEXPRO · SOMATROPIN 15MG/1.5ML · INJECTABLE, INJECTION · Prescription
- NORDITROPIN · SOMATROPIN 10MG/1.5ML · INJECTABLE, INJECTION · Discontinued
- NORDITROPIN FLEXPRO · SOMATROPIN 10MG/1.5ML · INJECTABLE, INJECTION · Prescription
- NORDITROPIN NORDIFLEX · SOMATROPIN 30MG/3ML · INJECTABLE, INJECTION · Discontinued
- NORDITROPIN NORDIFLEX · SOMATROPIN 10MG/1.5ML · INJECTABLE, INJECTION · Discontinued
- NORDITROPIN FLEXPRO · SOMATROPIN 30MG/3ML · INJECTABLE, INJECTION · Prescription
- NORDITROPIN · SOMATROPIN 15MG/1.5ML · INJECTABLE, INJECTION · Discontinued
- NORDITROPIN · SOMATROPIN 5MG/1.5ML · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Somatropin" as an intervention, any sponsor and status, largest first.
- Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in ChildrenStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT03290235 · 1,500 participants (planned) · Start Mar 1, 2017 · Primary completion Oct 2020
Drug: PEG-somatropin · For: Growth Retardation
Sites: Wuhan, China
- Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and RehabilitationPivotal-lookingTerminated
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT00675714 · 1,126 participants · Start Jan 2004 · Primary completion Sep 2018
Drug: Humatrope; Ketoconazole and 5 more · For: Burns
Sites: Galveston, Texas
- Current Status of Islet Alpha Cell Function in Patients with Type 2 DiabetesPivotal-lookingRecruiting
Nanjing First Hospital, Nanjing Medical UniversityAcademic, hospital or other
NCT06825182 · 1,000 participants (planned) · Start Nov 7, 2024 · Primary completion Aug 1, 2025
Drug: Outpatient newly diagnosed type 2 diabetes subjects; Inpatient newly diagnosed type 2 diabetes subjects · For: Type 2 Diabetes Mellitus
Sites: Nanjing, China
- Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone DeficiencyStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT03249480 · 900 participants (planned) · Start Jan 2015 · Primary completion Aug 2017
Drug: PEG-somatropin · For: Growth Hormone Deficiency
Sites: Hefei, China; Fuzhou, China; Guangzhou, China · 28 sites in all
- Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency ChildrenStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT02314676 · 900 participants (planned) · Start Nov 2014 · Primary completion Jul 2017
Drug: PEG-somatropin · For: Dwarfism, Pituitary
Sites: Wuhu, China; Hangzhou, China
- Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone DeficiencyPivotal-lookingStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT02908958 · 900 participants (planned) · Start Nov 2014 · Primary completion Jun 2017
Drug: PEG-somatropin; PEG-somatropin · For: Growth Hormone Deficiency
Sites: Hefei, China; Wuhu, China; Xiamen, China · 22 sites in all
- The Effect of Somatropin Treatment in Adult Patients on Chronic DialysisPivotal-lookingTerminated
Novo Nordisk A/SNovo Nordisk (NVO)
NCT00503698 · 712 participants · Start Jul 2007 · Primary completion Dec 2008
Drug: somatropin; placebo · For: Chronic Kidney Disease; End-Stage Renal Disease
Sites: Alexander City, Alabama; Birmingham, Alabama; Madison, Alabama · 381 sites in all
- Effect of GH Supplementation on the Blastocyst Euploid Rate in AMA Patients--A Retrospective Cohort StudyPivotal-lookingCompleted
ShangHai Ji Ai Genetics & IVF InstituteAcademic, hospital or other
NCT05574894 · 692 participants · Start Jan 1, 2021 · Primary completion Jun 30, 2022
Drug: Growth hormone; GnRH antagonist · For: Growth Hormone; Advanced Maternal Age; PGT-A
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use555
- headache406
- device leakage347
- injection site pain302
- fatigue262
- drug dose omission by device233
- drug ineffective233
- death204
- pyrexia202
- product dose omission issue187
- vomiting185
- nausea184
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 67 |
| 2005 | 35 |
| 2006 | 44 |
| 2007 | 149 |
| 2008 | 99 |
| 2009 | 276 |
| 2010 | 216 |
| 2011 | 253 |
| 2012 | 297 |
| 2013 | 145 |
| 2014 | 257 |
| 2015 | 371 |
| 2016 | 551 |
| 2017 | 477 |
| 2018 | 553 |
| 2019 | 726 |
| 2020 | 658 |
| 2021 | 545 |
| 2022 | 743 |
| 2023 | 991 |
| 2024 | 879 |
| 2025 | 672 |
| 2026 | 510 |
Recalls
1 FDA enforcement reports for this application.
Apr 27, 2016 · Class II · Terminated
Defective Delivery System; may have a low frequency assembly fault which may result in pens block during the so-called "air shot" step
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Norditropin Flexpro (Somatropin)
2024 spending
$16.4M
Beneficiaries
779
4,541 claims
Per beneficiary
$21,033
$1,069.83 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $17,154,790 |
| 2021 | $16,743,673 |
| 2022 | $17,359,212 |
| 2023 | $11,093,988 |
| 2024 | $16,384,406 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study.
Deal CL, Steelman J, Vlachopapadopoulou E, et al. · J Clin Endocrinol Metab 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency.
Kildemoes RJ, Hollensen C, Biller BMK, et al. · Eur J Endocrinol 2022 · Clinical Trial
- Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.
Thornton PS, Maniatis AK, Aghajanova E, et al. · J Clin Endocrinol Metab 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Physician experience with once-weekly somatrogon versus once-daily rhGH regimen in pediatric patients with growth hormone deficiency: a cross-sectional survey of physicians from the global phase 3 study.
Gomez R, Lamoureux R, Turner-Bowker DM, et al. · Front Endocrinol (Lausanne) 2023 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Systematic review of the clinical effectiveness of Genotropin (somatropin) in children with short stature.
Loftus J, Heatley R, Walsh C, et al. · J Pediatr Endocrinol Metab 2010 · Research Support, Non-U.S. Gov't, Systematic Review
- Efficacy and safety of Valtropin in the treatment of short stature in girls with Turner's syndrome.
Peterkova V, Savoy C, Bezlepkina O, et al. · J Pediatr Endocrinol Metab 2004 · Clinical Trial, Clinical Trial, Phase III
Sponsor: Novo Nordisk · Also marketed as Norditropin Nordiflex, Norditropin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.